## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%); PEG 3.59 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($526.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Advisory Services Network LLC Sells 2,312 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251216T090931 | Somewhat-Bullish | Relevance: 100%
- Advisory Services Network LLC reduced its stake in Medpace Holdings, Inc. by 14.6%, selling 2,312 shares and holding 13,473 shares valued at approximately $4.23 million. This transaction occurred amidst notable insider selling from Medpace executives and recent positive earnings results that surpassed analyst expectations. Medpace (NASDAQ:MEDP) reported $3.86 EPS against an estimated $3.50, with revenues up 23.7% year-over-year, and has set strong FY2025 guidance.

**2. Medpace price target raised to $525 from $485 at Barclays**
- Source: TipRanks | 20251215T122118 | Somewhat-Bullish | Relevance: 100%
- Barclays analyst Luke Sergott has increased the price target for Medpace (MEDP) to $525 from $485, while maintaining an Underweight rating. This adjustment is part of the firm's 2026 outlook for the life sciences and diagnostics tools sector, with the analyst suggesting a positive setup for outperformance in the tools group for 2026 due to anticipated market recovery and the sector being "most under-owned" in healthcare.

**3. Medpace Holdings, Inc. $MEDP is Bares Capital Management Inc.'s 8th Largest Position**
- Source: MarketBeat | 20251213T090945 | Somewhat-Bullish | Relevance: 100%
- Bares Capital Management Inc. significantly increased its stake in Medpace Holdings, Inc. ($MEDP) by 319.2% in the second quarter, making it their 8th largest position. Medpace comprises 4.8% of the fund's investment portfolio. Several other institutional investors have also adjusted their holdings, while numerous Wall Street analysts have issued ratings and price target adjustments for the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $525 | $485 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.82M) |
| Sells | 29 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $217M sold (29 transactions in 90 days).
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +7.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.59 signals overvaluation risk, limited margin of safety. Forward P/E 33.9x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.7B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.59 |
| Forward P/E | 33.9 |
| Current P/E | 37.0 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.1% to 1.7% (+7.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 1.8% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-3.80), momentum weakening. RSI neutral at 44. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.74% (CS: 45) | Neutral |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -3.80 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 1.340x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $559.13
- **Stop Loss:** $526.29 (5.9% risk)
- **Target:** $591.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $20,128.68
- **Portfolio %:** 20.13%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*